Next-Gen Cancer Care: Bispecifics, Smart Dosing, and System-Level Thinking at ESMO 2025

The opening day of the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin—one of oncology’s largest international meetings—set the stage for a transformative decade in cancer care. With more than 35,000 participants and 2,900 selected abstracts, the event showcased how molecular biology, data analytics, and clinical pragmatism are converging to redefine precision oncology. Beyond drug approvals, the discussions reflected an industry moving toward smarter trial design, adaptive dosing, and patient-centered endpoints.

Bispecific HER2 Therapy Extends Survival in Gastric and GE Junction Cancer

A bispecific antibody targeting HER2-positive gastric and gastroesophageal junction cancer (GC/GEJC) achieved notable results in patients previously treated with trastuzumab. The KC-WISE study compared the bispecific agent plus chemotherapy against standard therapy, reporting an objective response rate (ORR) of 55% versus 10.8%, median progression-free survival (mPFS) of 7.1 vs. 2.7 months, and median overall survival (mOS) of 19.6 vs. 11.5 months.

The findings confirm that refined antibody engineering—capable of dual-epitope binding—can extend clinical benefit even in resistant settings. So, for a disease that has long seen diminishing returns with subsequent lines of therapy, this trial demonstrates how next-generation HER2 agents can re-engage immune activity and overcome tumor heterogeneity. In practical terms, the data also signal where investment is flowing: bispecifics and modular ADCs are rapidly emerging as the most flexible oncology platforms, capable of expanding across tumor types.

CDK4/6 Inhibition Solidifies Its Role in Early Breast Cancer

Long-term updates from several adjuvant trials confirmed that CDK4/6 inhibitors have moved beyond experimental adjuncts into durable components of care for hormone receptor-positive (HR+), HER2-negative early breast cancer.

The NATALEE trial, enrolling over 5,100 patients with stage II–III disease, evaluated ribociclib (400 mg daily, 3 weeks on/1 week off) plus aromatase inhibitor versus endocrine therapy alone. After a median follow-up of 55 months, results showed a hazard ratio of 0.716 (p < 0.0001) for invasive disease-free survival (IDFS), corresponding to a 4.5% absolute improvement at five years (85.5% vs. 81.0%). Notably, even node-negative and lower-risk subgroups benefited (HR 0.606), expanding the eligible population for adjuvant therapy.

Updated monarchE trial data, simultaneously published in Annals of Oncology, demonstrated a 1.8% overall survival advantage at seven years (HR 0.842; 95% CI 0.722–0.981; P = 0.027) with abemaciclib plus endocrine therapy in high-risk patients—especially in premenopausal women and those with heavy nodal burden.

These findings reinforce a durable, biologically consistent pattern: cell-cycle inhibition lowers recurrence risk across the risk spectrum. However, they also introduce new debates—about treatment duration, cost, and quality of life. Given this, it appears that the field is now balancing modest absolute gains with the value of extending the recurrence-free window, particularly in node-negative or younger cohorts.

Rethinking Chemotherapy Intensity in Urothelial Carcinoma

The DISCUS trial (NCT06892860), a phase II investigator-led study, tackled a long-standing clinical dilemma: how many cycles of platinum chemotherapy are enough before maintenance immunotherapy in advanced urothelial carcinoma?

The trial compared three versus six cycles of platinum chemotherapy, both followed by maintenance avelumab. Results showed comparable progression-free survival (PFS 8.0 vs 9.0 months), overall survival (OS 18.9 months in both arms; HR 1.15, 95% CI 0.72–1.86), and objective response rates (24% vs 27%), but with superior patient-reported quality of life in the three-cycle arm. Importantly, a greater proportion of patients in the three-cycle group were able to transition to avelumab maintenance (74% vs 56%), and Grade 3–4 adverse events were less frequent (11.9% vs 15.7%). 

Presented alongside a simultaneous Annals of Oncology publication, DISCUS suggests that de-escalation strategies can preserve efficacy while reducing toxicity and treatment fatigue. For industry, this represents a growing shift toward endpoint diversity—where quality of life and treatment sustainability are weighted alongside efficacy in late-phase trial design.

Local Consolidation Strengthens Outcomes in EGFR-Mutant Lung Cancer

The NorthStar phase II trial (LBA72) evaluated whether adding local consolidation therapy (LCT)—via surgery or radiotherapy—to first-line osimertinib could extend survival in EGFR-mutant non-small cell lung cancer (NSCLC).

Patients receiving osimertinib plus LCT achieved a median progression-free survival (mPFS) of 25.3 months versus 17.5 months with osimertinib alone (HR 0.66), with the benefit observed across mutation subtypes and metastatic burdens.  The advantage held across mutation subtypes and varying metastatic burden.

This reinforces a growing principle in thoracic oncology: precisely timed local therapy can suppress resistant clones and prolong systemic control. The trial also highlights the direction of future combination strategies—integrating targeted agents with localized disease stabilization rather than escalating systemic toxicity, and prompting new questions about which patients benefit most, when LCT should be delivered, and how future trials should define optimal endpoints for integrated local-systemic strategies.

Hypoxia Pathway Targeting Gains Traction in Rare Neuroendocrine Tumors

The LITESPARK-015 trial (NCT04924075) evaluated belzutifan, a first-in-class inhibitor of hypoxia-inducible factor 2-alpha (HIF-2α), in metastatic pheochromocytoma and paraganglioma (PPGL). These are rare, often treatment-resistant neuroendocrine tumors driven by HIF pathway dysregulation.

Results showed an objective response rate of approximately 40%, with median PFS exceeding 14 months and durable disease control beyond 12 months in many patients. Side effects were mild—mainly anemia and fatigue—with hypertension in fewer than 10% of cases.

Belzutifan’s activity confirms that metabolic signaling pathways—once considered secondary to immune or genetic drivers—can produce clinically meaningful and well-tolerated responses. The drug’s oral dosing and predictable safety profile also open the door to combination approaches with immunotherapy or anti-angiogenic agents.

Long-Term CML Data Point to Smarter Dosing, Not Just New Drugs

In hematology, a retrospective analysis of 665 patients with chronic myeloid leukemia (CML) provided a rare longitudinal look at treatment sequencing over nearly two decades.

Most patients were in chronic phase at diagnosis. Thirty-four percent switched therapy due to resistance, 29% due to intolerance, and 25% for both reasons. After moving to second-line (2L) TKIs, 42% achieved complete cytogenetic response (CCyR) and 37% reached major molecular response (MMR). Ponatinib showed the strongest second-line activity, inducing CCyR in 75% (9/12) and MMR in 40% (8/20) of refractory cases. After nearly ten years of follow-up, overall survival reached 70%, with event-free and transformation-free survival at 55% and 74%, respectively.

These results reaffirm that treatment optimization—not merely therapy replacement—is key to long-term disease control. As companies like Novartis and Takeda invest in AI-driven dose modeling and real-time molecular monitoring, the field is trending toward adaptive precision—tailoring intensity rather than continuously switching drugs.

Recognition, Collaboration, and the Broader Context of Progress

Beyond the data, Day 1 underscored how oncology continues to advance through global collaboration and long-term commitment to patient access and education. Dr. Glenda Ramos Martínez, recognized as Ecuador’s first female medical oncologist, received the inaugural ESMO Oncologist of the Year Award for her decades of work expanding equitable cancer care in Latin America. Over more than 30 years, she has strengthened oncology training, improved access to essential medicines through her role on Ecuador’s National Commission of Medicines and Supplies, and led nationwide public-awareness initiatives such as “Don’t Give Cancer a Chance,” which promotes prevention, screening, and early diagnosis. Her recognition reflected a broader theme of the congress—how local leadership and health-system reform can translate into tangible improvements in care delivery.

Prof. Rolf Stahel and Dr. Natasha Leighl were also commended for advancing international mentorship and clinical standards, while discussions on digital health and AI explored how technology can further bridge gaps in access, education, and treatment equity worldwide.

From Targets to Systems Thinking

Across tumor types and treatment modalities, the message was consistent: oncology is shifting from targeting isolated mutations to understanding how systems of biology interact and respond. Whether through ctDNA tracking, tumor-agnostic trials, or adaptive dose modeling, the next generation of therapies will rely on integrating molecular insight, patient data, and computational modeling.

For biotech and pharmaceutical stakeholders, this signals a new kind of competition—where success depends as much on data interpretation and trial efficiency as on molecular innovation itself. Cancer research is no longer just about finding the next target; it’s about predicting the next move of the disease.

Author

Bernice Lottering